Havens Comments on FDA's Review of Incorporating CBD into Dietary Supplements

Published

FDA takes another look at CBD, but insiders are skeptical much will change

U.S. health regulators are taking their closest look in more than three years at the idea of incorporating cannabinoids into dietary supplements.

But hopes are dim that Tuesday’s daylong review by the U.S. Food and Drug Administration’s Science Board will finally deliver a path to treating CBD like other dietary supplements – regulated but sold without prescriptions.

“I don’t view this as an attempt by FDA to try to move the needle. I just see this as them kind of building up their dossier of why they’re not going to be easing the burdens for industry,” said Jonathan Havens, a Washington DC-based cannabis attorney with Saul Ewing.

Read Full Article on mjbizdaily.com
Related Professional
Jonathan A. Havens
Related Industries